Alprazolam XR 2 mg

Product Description

Alprazolam XR 2 mg tablets provide an extended-release formulation of the triazolobenzodiazepine alprazolam, specifically engineered to overcome the sharp peak-and-trough plasma oscillations associated with immediate-release alprazolam. Indicated for the maintenance treatment of panic disorder, this once-daily regimen maintains steady-state therapeutic coverage throughout a 24-hour dosing interval, reducing breakthrough panic attacks and minimizing inter-dose rebound anxiety.

Clinical Profile & Physical Presentation

• Active Ingredient: Alprazolam (2 mg per tablet).

• Dosage Form & Appearance: Typically manufactured as a pentagonal or round, film-coated extended-release tablet (e.g., branded Xanax XR 2 mg appears as a blue, pentagonal tablet debossed with an “X” and “2”).

• Controlled-Release Technology: Utilizes a hydrophilic hypromellose (HPMC) polymer matrix. Upon ingestion, gastrointestinal fluids hydrate the tablet surface, forming a viscous gel barrier through which active alprazolam gradually diffuses at a constant rate throughout the digestive transit.

Pharmacodynamics & Mechanism of Action

• GABA Receptor Modulation: Binds stereospecifically to the benzodiazepine regulatory site located between the $\alpha$ and $\gamma$ subunits of the pentameric $\text{GABA}_\text{A}$ chloride-channel receptor complex.

• Inhibitory Hyperpolarization: Enhances the affinity of endogenous gamma-aminobutyric acid ($\text{GABA}$) for its binding site, increasing the opening frequency of the intrinsic chloride channel pore. The resulting influx of chloride ions hyperpolarizes the neuronal membrane, attenuating neuronal excitability and dampening hyperactive transmission across the amygdala, hippocampus, and locus coeruleus.

Pharmacokinetics & Metabolism

• Absorption & Bioavailability: Absorbed at a steady rate following oral administration; peak plasma concentrations ($C_{\max}$) are reached between 5 to 11 hours post-dose (compared to 1 to 2 hours for immediate-release alprazolam). Absolute bioavailability is equivalent to immediate-release formulations (~90%).

• Metabolism: Primarily metabolized in the liver via cytochrome P450 3A4 (CYP3A4) to primary metabolites 4-hydroxyalprazolam and $\alpha$-hydroxyalprazolam, both of which possess minimal clinical activity relative to the parent compound.

• Elimination: Mean plasma elimination half-life is approximately 11 to 15 hours in healthy adults, with clearance occurring primarily via renal excretion of polar glucuronide conjugates.

Prescribing Guidelines & Administration Protocol

• Administration Integrity: Tablets must be swallowed whole once daily (preferably in the morning) and must never be chewed, crushed, split, or dissolved. Disruption of the tablet matrix destroys the extended-release mechanism, precipitating rapid drug release (“dose dumping”) and immediate toxicity.

• Dosing Individualization: Titration must proceed gradually at intervals of no less than 3 to 4 days. When discontinuing therapy, daily dosages must be slowly tapered under strict medical oversight to prevent severe rebound symptoms.

Important Safety Information & Boxed Warnings

• Concomitant Opioid Risk: Co-administration of benzodiazepines and opioids may cause profound sedation, respiratory depression, coma, and death. Limit dosages and durations to the minimum required in patients without alternative treatment modalities.

• Abuse, Misuse, and Addiction: Alprazolam XR is a Schedule IV controlled substance carrying significant risks of misuse, abuse, and diversion, which can lead to overdose and life-threatening toxicity.

• Physical Dependence & Severe Withdrawal: Continued use produces physiological dependence. Abrupt discontinuation or rapid dosage reduction can produce acute, life-threatening withdrawal symptoms, including status epilepticus, delirium tremens, catatonia, and severe tremors.

• CYP3A4 Inhibitor Contraindication: Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) is contraindicated due to substantial increases in alprazolam plasma concentrations.